<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">M Kontos</style></author><author><style face="normal" font="default" size="100%">Roy, P.</style></author><author><style face="normal" font="default" size="100%">Rizos, D.</style></author><author><style face="normal" font="default" size="100%">Hamed, H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">An evidence based strategy for follow up after breast conserving treatment for breast cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Surgical Oncology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">oncology</style></keyword><keyword><style  face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style  face="normal" font="default" size="100%">surgery</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011///</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">104</style></volume><pages><style face="normal" font="default" size="100%">223 - 227</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Background and Objectives Follow up for breast cancer patients aims at the timely detection of loco-regional recurrences and contralateral breast cancers (LRR). This study investigates the annual risk of LRR after breast conserving treatment (BCT) and the potential value of mammographic surveillance and/or routine clinical examination. Methods Data on 650 women who underwent BCT were obtained and LRR was divided into parenchymal and non-parenchymal. LRR-free and cumulative LRR-free rates were calculated. In patients where recurrence was diagnosed at a routine clinic visit and had negative mammography (&quot;clinical detection only&quot; group) were also separately examined. Results Median follow up was 115 months, range 9-196. Seventy-three patients had parenchymal and 16 nodal recurrence. The median probability of LRR was 1.4% and of parenchymal LRR was 1.32% per year, remaining constant for up to 168 months. The 16 patients in the &quot;clinical detection only&quot; group relapsed mainly during the first 2 years (annual risk 0.77% and 0.80%, respectively). Conclusions This study shows that the risk of parenchymal LRR remains constant for at least 14 years and is significant enough to warrant routine long-term follow up mammography. Routine clinical examination contributes significantly to the detection of LRR only for the first 2 years. © 2011 Wiley-Liss, Inc.</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue></record></records></xml>